American Well $356.8 million secondary offering
We advised Amwell on the stock offering
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Affimed $115 million offering of shares
We advised the underwriters on the public equity offering
REGENXBIO $230.3 million stock offering
We advised the underwriters on a public equity offering
Generation Bio $225.4 million stock offering
We advised the underwriters on the public equity offering
NeoGenomics $230 million stock and $345 million convertible notes offerings
We advised the joint book-running managers on the public offerings of stock and convertible notes
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
NGM Biopharmaceuticals $125 million follow-on offering
We advised the joint book-running managers on the public equity offering
Gamida Cell $75 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $75 million SEC-registered follow-on offering of 9,343,750 ordinary shares of Gamida Cell Ltd, which…
Solid Biosciences $90 million common stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Solid Biosciences Inc. of $90 million of common stock.
Solid Biosciences Inc…
Atara Biotherapeutics $175 million common stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants…